PMID- 26546407
OWN - NLM
STAT- MEDLINE
DCOM- 20160229
LR  - 20181202
IS  - 1534-6315 (Electronic)
IS  - 1529-7322 (Linking)
VI  - 15
IP  - 12
DP  - 2015 Dec
TI  - New Insights into Eosinophilic Otitis Media.
PG  - 76
LID - 10.1007/s11882-015-0577-2 [doi]
AB  - Eosinophilic otitis media (EOM) is a type of intractable otitis media that occurs 
      mainly in patients with bronchial asthma (BA). In 2011, the diagnostic criteria 
      for EOM were established. EOM is characterized by the presence of a highly 
      viscous yellowish effusion containing eosinophils and immunoglobulin E (IgE), 
      eosinophil chemoattractants, such as eosinophil cationic protein, interleukin-5, 
      and eotaxin. Local sensitization against foreign agents such as fungi or bacteria 
      (e.g., Staphylococcus aureus) may result in local IgE production in the middle 
      ear and may be responsible for the severity of EOM. The clinical features of EOM 
      closely resemble localized eosinophilic granulomatosis polyangiitis, therefore it 
      is necessary to be vigilant to the symptoms of mononeuritis, polyneuritis, and 
      skin purpura during diagnosis. Standard treatment for EOM is the instillation of 
      triamcinolone acetonide into the mesotympanum. However, severe cases exhibiting 
      strong inflammation and otorrhea are not easily controlled with antibiotics 
      and/or corticosteroids. We proposed the introduction of a severity score to 
      evaluate the severity of EOM. This score correlated with local IgE levels in 
      middle ear effusion. Clinically, the risk factors associated with this severity 
      score were body mass index, and the duration of bronchial asthma (from the onset 
      of BA to the age of the first consultation of otitis media to our hospital). We 
      emphasize that early diagnosis and adequate treatment are vital in preventing 
      progressive and sudden hearing loss resulting from EOM.
FAU - Kanazawa, Hiromi
AU  - Kanazawa H
AD  - Department of Otolaryngology, Jichi Medical University Saitama Medical Center, 
      1-847 Amanuma, Omiya-ku, Saitama, 330-8503, Japan. hkanazawa@jichi.ac.jp.
FAU - Yoshida, Naohiro
AU  - Yoshida N
AD  - Department of Otolaryngology, Jichi Medical University Saitama Medical Center, 
      1-847 Amanuma, Omiya-ku, Saitama, 330-8503, Japan. naoyoshida@jichi.ac.jp.
FAU - Iino, Yukiko
AU  - Iino Y
AD  - Department of Otolaryngology, Tokyo-Kita Medical Center, Tokyo, Japan. 
      yiino@jichi.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Age Distribution
MH  - Animals
MH  - Asthma/drug therapy/*immunology
MH  - Eosinophilia/*immunology
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Otitis Media/drug therapy/*immunology
MH  - Otitis Media with Effusion/immunology
OTO - NOTNLM
OT  - Bronchial asthma
OT  - Eosinophilic chronic rhinosinusitis
OT  - Eosinophilic otitis media
OT  - Immunoglobulin E
OT  - Severity score
OT  - Viscous middle ear effusion
EDAT- 2015/11/08 06:00
MHDA- 2016/03/02 06:00
CRDT- 2015/11/08 06:00
PHST- 2015/11/08 06:00 [entrez]
PHST- 2015/11/08 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
AID - 10.1007/s11882-015-0577-2 [pii]
AID - 10.1007/s11882-015-0577-2 [doi]
PST - ppublish
SO  - Curr Allergy Asthma Rep. 2015 Dec;15(12):76. doi: 10.1007/s11882-015-0577-2.